3 668

Cited 12 times in

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naive chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort

DC Field Value Language
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.contributor.author안성수-
dc.contributor.author한광협-
dc.contributor.author김도영-
dc.date.accessioned2015-01-06T17:26:20Z-
dc.date.available2015-01-06T17:26:20Z-
dc.date.issued2014-
dc.identifier.issn2287-2728-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/99980-
dc.description.abstractBackground/Aims: This study assessed the antiviral efficacy and safety of tenofovir disoproxil fumarate (TDF) for up to 12 months in Korean treatment-naive chronic hepatitis B (CHB) patients. Methods: A total of 411 treatment-naive CHB patients who had been treated with TDF for at least 3 months (median 5.6) were consecutively enrolled. Clinical, biochemical, virological parameters and treatment adherence were routinely assessed every 3 months. Results: The median age was 51.3 years, 63.0% of the patients were male, 49.6% were HBeAg (+), and 210 patients had liver cirrhosis. The median baseline HBV DNA was 5.98 (SD 1.68) log10 IU/mL. Among the patients completing week 48, 83.3% had a complete virologic response (CVR, <12 IU/mL by HBV PCR assay), and 88.2% had normalized levels of alanine aminotransferase (ALT). The cumulative probabilities of CVR at 3, 6, 9 and 12 months were 22.8 %, 53.1%, 69.3% and 85.0%. During the follow-up period, 9.8% patients achieved HBeAg loss and 7.8% patients achieved HBeAg seroconversion. There was no virological breakthrough after initiating TDF. The most common TDF-related adverse event was gastrointestinal upset, and three patients discontinued TDF therapy. However, no serious life-threatening side effect was noted. Conclusions: In a clinical practice setting, TDF was safe and highly effective when administered for 12 months to Korean treatment-naive CHB patients.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.relation.isPartOfCLINICAL AND MOLECULAR HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenine/adverse effects-
dc.subject.MESHAdenine/analogs & derivatives*-
dc.subject.MESHAdenine/therapeutic use-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAlanine Transaminase/blood-
dc.subject.MESHAntiviral Agents/adverse effects-
dc.subject.MESHAntiviral Agents/therapeutic use*-
dc.subject.MESHCohort Studies-
dc.subject.MESHDNA, Viral/blood-
dc.subject.MESHFemale-
dc.subject.MESHGastrointestinal Diseases/epidemiology-
dc.subject.MESHGastrointestinal Diseases/etiology-
dc.subject.MESHHepatitis B e Antigens/blood-
dc.subject.MESHHepatitis B virus/genetics-
dc.subject.MESHHepatitis B, Chronic/complications-
dc.subject.MESHHepatitis B, Chronic/drug therapy*-
dc.subject.MESHHepatitis B, Chronic/virology-
dc.subject.MESHHumans-
dc.subject.MESHLiver Cirrhosis/etiology-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHOrganophosphonates/adverse effects-
dc.subject.MESHOrganophosphonates/therapeutic use*-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTenofovir-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHYoung Adult-
dc.titleTenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naive chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorSung Soo Ahn-
dc.contributor.googleauthorYoung Eun Chon-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorKwang Hyub Han-
dc.contributor.googleauthorJun Yong Park-
dc.identifier.doi10.3350/cmh.2014.20.3.261-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA04268-
dc.contributor.localIdA02233-
dc.contributor.localIdA00385-
dc.relation.journalcodeJ00557-
dc.identifier.eissn2287-285X-
dc.identifier.pmid25320729-
dc.subject.keywordChronic hepatitis B-
dc.subject.keywordKorean-
dc.subject.keywordReal-life-
dc.subject.keywordTenofovir-
dc.contributor.alternativeNameKim, Beom Kyung-
dc.contributor.alternativeNameKim, Seung Up-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.alternativeNameAhn, Sung Soo-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthorKim, Beom Kyung-
dc.contributor.affiliatedAuthorKim, Seung Up-
dc.contributor.affiliatedAuthorPark, Jun Yong-
dc.contributor.affiliatedAuthorAhn, Sang Hoon-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.contributor.affiliatedAuthorAhn, Sung Soo-
dc.contributor.affiliatedAuthorKim, Do Young-
dc.citation.volume20-
dc.citation.number3-
dc.citation.startPage261-
dc.citation.endPage266-
dc.identifier.bibliographicCitationCLINICAL AND MOLECULAR HEPATOLOGY, Vol.20(3) : 261-266, 2014-
dc.identifier.rimsid54386-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.